HIPRA Group closed 2024 with a turnover of 440.2 million euros and a net profit of 32.7 million euros. These results are the outcome of the good development of the division specializing in animal health and reflect the great investment that the company is making in the field of human health, as well as the investment efforts made in cutting-edge facilities and innovation.

During the year, the company has invested more than 92 million euros in R+D and facilities, thus reaffirming its commitment to innovation as an axis of growth. Investment in R+D has reached 62 million euros, which represents 14% of annual turnover, in addition to the 255 million invested from 2019 to 2023. This sustained effort is part of the company’s long-term vision and demonstrates HIPRA's commitment to position innovation as the cornerstone of its business model.

In 2024, HIPRA's EBITDA stood at 89.2 million euros, reflecting the stability of the business in a context of strong investment. The company maintains its commitment to the development of new products and the promotion of the human health division, created in 2021, which in just 4 years has achieved an exceptional milestone: registering a vaccine for human health, a process that usually requires a decade. Despite the increase in demand for resources in long-term projects, HIPRA maintains solid operating profitability, in line with its roadmap for growth and international diversification.

In line with its financial strategy, the company has reduced its net debt by €8.3 million, placing it at €157.8 million, equivalent to 1.7 EBITDA, on the back of combined investment, a commitment to new projects and a solid financial structure.